ArticleAngewandte Chemie (International ed. in English)2020
An Aptamer-Nanotrain Assembled from Six-Letter DNA Delivers Doxorubicin Selectively to Liver Cancer Cells.
Article in Angewandte Chemie (International ed. in English), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 92 citations in OpenAlex.
- Structural basis of transcription of the hachimoji eight-letter alphabet by E. coli RNA polymerase.Nature communications · 2026Article
- Expanding DNA alphabet adds a previously unknown dimension to nanostructures.Science advances · 2026Article
- Recognition of unnatural base pairs by a eukaryotic DNA polymerase enables universal sequencing of an expanded genetic alphabet.Nucleic acids research · 2026Article
- Improving the Fidelity of Replication of a Six-Letter DNA Alphabet.ACS chemical biology · 2025Article
- Dynamic PET Imaging of EpCAM-Positive Colorectal Cancer Using Radiolabeled DTN-SYL3C Aptamer Conjugates.ACS omega · 2025Article
- Sequencing a DNA analog composed of artificial bases.Nature communications · 2025Article
- Cancer cell target discovery: comparing laboratory evolution of expanded DNA six-nucleotide alphabets with standard four-nucleotide alphabets.Nucleic acids research · 2025Article
- Nucleic acid joining enzymes: biological functions and synthetic applications beyond DNA.The Biochemical journal · 2025Review
- Six-Letter DNA Nanotechnology: Incorporation ofNano letters · 2024Article
- Sulfonated Azocalix[4]arene-Modified Metal-Organic Framework Nanosheets for Doxorubicin Removal from Serum.Nanomaterials (Basel, Switzerland) · 2024Article
- Enzyme-assisted high throughput sequencing of an expanded genetic alphabet at single base resolution.Nature communications · 2024Article
- The Application of Aptamer and Research Progress in Liver Disease.Molecular biotechnology · 2024Review
- Enzyme-Assisted High Throughput Sequencing of an Expanded Genetic Alphabet at Single Base Resolution.Research square · 2023Article
- Aptamer-based nanotrains and nanoflowers as quinine delivery systems.International journal of pharmaceutics: X · 2023Article
- Exploring the diverse biomedical applications of programmable and multifunctional DNA nanomaterials.Journal of nanobiotechnology · 2023Review
- A micelle-based stage-by-stage impelled system for efficient doxorubicin delivery.Bioactive materials · 2023Article
- Synthetic Biology Pathway to Nucleoside Triphosphates for Expanded Genetic Alphabets.ACS synthetic biology · 2023Article
- Assessing Readability of an 8-Letter Expanded Deoxyribonucleic Acid Alphabet with Nanopores.Journal of the American Chemical Society · 2023Article
- Recent progress of aptamer‒drug conjugates in cancer therapy.Acta pharmaceutica Sinica. B · 2023Review
- Rethinking nucleic acids from their origins to their applications.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Expanding the number of nucleotides in DNA increases the information density of functional DNA molecules, creating nanoassemblies that cannot be invaded by natural DNA/RNA in complex biological systems. Here, we show how six-letter GACTZP DNA contributes this property in two parts of a nanoassembly: 1) in an aptamer evolved from a six-letter DNA library to selectively bind liver cancer cells; and 2) in a six-letter self-assembling GACTZP nanotrain that carries the drug doxorubicin. The aptamer-nanotrain assembly, charged with doxorubicin, selectively kills liver cancer cells in culture, as the selectivity of the aptamer binding directs doxorubicin into the aptamer-targeted cells. The assembly does not kill untransformed cells that the aptamer does not bind. This architecture, built with an expanded genetic alphabet, is reminiscent of antibodies conjugated to drugs, which presumably act by this mechanism as well, but with the antibody replaced by an aptamer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.